Emerging Role of Dual GLP 1 and GIP Receptor Agonists DMSO Dove Medical Press Efficacy and safety of incretin co agonists: Transformative advances in cardiometabolic healthcare Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Incretins in Cardiometabolic Medicine: Leveraging GLP 1, GIP, and Glucagon Receptor Agonism for Cardiovascular Risk Reduction Glucagon like peptide 1 (GLP 1) receptor agonists are incretin analogues that promote glucose mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP 1 receptor agonists and GLP 1 and glucose dependent insulinotropic